China suggests COVID-19 originated in US in response to Trump allegation

Reuters
04/30
UPDATE 1-China suggests COVID-19 originated in US in response to Trump allegation

Updates throughout with details from white paper, context

BEIJING, April 30 (Reuters) - China restated its case that COVID-19 may have originated in the United States in a white paper on its pandemic response released on Wednesday after President Donald Trump's administration blamed a lab leak in China.

The White House launched a COVID-19 website on April 18 in which it said the coronavirus came from a lab leak in China while criticising former President Joe Biden, former top U.S. health official Anthony Fauci and the World Health Organization.

In the white paper, released by the official Xinhua news agency, China accused the U.S. of politicising the matter of the origins of COVID-19. It cited a Missouri lawsuit which resulted in a $24 billion ruling against China for hoarding protective medical equipment and covering up the outbreak.

China shared relevant information with the WHO and the international community in a timely manner, the white paper said, emphasising that a joint study by the WHO and China had concluded that a lab leak was "extremely unlikely".

The U.S. should not continue to "pretend to be deaf and dumb", but should respond to the legitimate concerns of the international community, the white paper said.

"Substantial evidence suggested the COVID-19 might have emerged in the United States earlier than its officially-claimed timeline, and earlier than the outbreak in China," it said.

The CIA said in January the pandemic was more likely to have emerged from a lab in China than from nature, after the agency had for years said it could not reach a conclusion on the matter. It said it had "low confidence" in its new assessment and noted that both lab origin and natural origin remain plausible.

An official at China's National Health Commission said the next step in origin-tracing work should focus on the U.S., according to Xinhua, which cited a statement about the white paper.

(Reporting by Xiuhao Chen, Ethan Wang and Joe Cash; Editing by Christian Schmollinger and Philippa Fletcher)

((Xiuhao.Chen@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10